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AML relapsing as ALL has rarely been reported. We describe the case of a 62-yr-old man who was diagnosed with erythroleukemia 
with a complex karyotype and achieved complete hematologic and cytogenetic remission after induction chemotherapy. Howev-
er, 4 months after the initial diagnosis, he showed relapse with blasts showing a different morphology and immunophenotype 
and was diagnosed with precursor B-cell ALL. The relapsing precursor B-cell ALL presented with the same leukemic clones as the 
primary erythroleukemia. Cytogenetic analysis of his bone marrow (BM) at the time of the primary erythroleukemia showed com-
plex karyotypic abnormalities, including monosomy 5 and monosomy 7. At relapse, his BM showed reemergence of these leuke-
mic clones of complex karyotypic abnormalities with clonal switch. To our knowledge, this is the first case of a lineage switch from 
erythroleukemia to ALL.
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INTRODUCTION
Lineage switch in relapsing leukemia is a rare event. The 
rate of conversion from ALL to AML has been found to be 
6-9%, and most of the lineage switches have been reported 
in children [1-5]. In contrast, conversion from AML to ALL 
is extremely rare in children [6-11]; further, only 3 such 
cases have been reported in adults [12-14]. To our knowl-
edge, no cases of conversion from erythroleukemia to ALL 
have been reported to date. In cases showing relapse with 
lineage switch, most leukemic clones have a different mor-
phology, phenotypic lineage, and distinct molecular charac-
teristics. In general, the time between initial diagnosis and 
relapse with lineage switch is 1-4 yr [1]. We describe the 
case of an adult patient with erythroleukemia who showed 
ALL relapse only 4 months after initial diagnosis; the re-
lapsed ALL presented with cells showing a different mor-
phological and phenotypic lineage but with the same clones 
and some clonal evolution.
CASE REPORT
A 62-yr-old male patient presented with dyspnea and 
pancytopenia. Neither splenomegaly nor lymphadenopathy 
was found. He had no previous medical history. Peripheral 
blood analysis yielded the following findings: hemoglobin, 
5.6 g/dL; platelet count, 126×10
9/L; and leukocyte count, 
2.2×10
9/L, with 88% lymphocytes, 6% segmented neutro-
phils, 2% monocytes, 1% myelocytes, 1% eosinophils, 1% 
basophils, and 1% atypical lymphocytes.
Bone marrow (BM) analysis revealed that 52% of the nu-
cleated cells were erythroid precursors and that 39.2% of the 
non-erythroid cells were blasts with 2 types of morphology. 
The predominant blasts were small- to medium-sized with 
dispersed nuclear chromatin, 2 or 3 prominent nucleoli, and 
a moderate amount of cytoplasm, with a few blasts contain-
ing cytoplasmic vacuoles (Fig. 1A). None of the hematopoi-
etic cell lineages showed dysplastic features. In a cytochemi-
cal analysis, the blasts were positive for myeloperoxidase 
(MPO) but negative for α-naphthyl butyrate esterase (ANBE) 
and periodic acid Schiff (PAS) stains. All erythroid precur-
sors were negative for PAS. A few blasts with cytoplasmic 
vacuoles were negative for MPO and PAS stains. Flow-cyto-82     www.kjlm.org
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metric immunophenotyping of the blasts showed positivity 
for CD34 and markers of myeloid lineage, such as CD13, 
CD15, CD33, CD117, and CD65, with aberrant expression 
of CD2 and CD19 (Table 1). Immunophenotypically, the 
blasts were positive for both myeloid and some lymphoid 
markers, such as CD19, but a population of blasts was not 
divided into two populations by immunophenotypic analy-
sis. Cytogenetic analysis of the patient’s BM cells showed 
characteristics of 41,XY,-5,-7,add(11)(q23),der(14;21)(q10; 
q10),-16,add(17)(p13),-18,-20,-21,-22,+2mar[20]. A BM bi-
opsy showed 60% cellularity and several nodules composed 
of leukemic blasts.
We made a diagnosis of erythroleukemia and started in-
duction chemotherapy with cytarabine and daunorubicin. 
After the first course of induction treatment, the patient’s 
BM analysis still showed 9.6% blast cells; therefore, we per-
formed reinduction therapy with cytarabine and daunoru-
bicin. Two months after the initial diagnosis, complete re-
mission was achieved and cytogenetic analysis of the pa-
tient’s BM showed a normal karyotype of 46,XY[20]. Con-
solidation chemotherapy was continued with cytarabine, 
and the remission was maintained for 2 months.
Four months after the initial diagnosis, the patient pre-
sented with peripheral leukocytosis, anemia, and thrombo-
cytopenia. Peripheral blood analysis yielded the following 
results: hemoglobin, 9.4 g/dL, platelet count, 20×10
9/L, and 
leukocyte count, 15.5×10
9/L, with 30% blasts. In the BM 
analysis, 91.2% of all nucleated cells were blasts. At relapse, 
the blasts had large, irregularly shaped nuclei with fine chro-
matin, inconspicuous nucleoli, and a moderate amount of 
light blue cytoplasm with many vacuoles (Fig. 1B). The 
small proportion of blasts with cytoplasmic vacuoles at the 
initial diagnosis became predominant in the relapse. The 
blasts did not stain with the MPO and ANBE stains, but 
they showed positive staining with the PAS stain, with a 
coarse, granular positivity pattern. Immunophenotyping of 
the blasts revealed positivity for CD34, CD13, CD15, CD19, 
cytoplasmic CD22, terminal deoxynucleotidyl transferase 
(TDT), CD65, and CD79α and absence of anti-myeloperox-
idase (Table 1). The karyotype of the BM cells in the relaps-
ing condition was 41,XY,add(1)(q21),-3,add(3)(q22),-4,-5, 
-7,der(9)t(9;11)(q34;q13),der(11)del(11)(p11.2)add(11)
(q23), der(14;21)(q10;q10),-16,add(17)(p13),-18,-20, 
-22,+4mar[20]. A BM biopsy showed 70% cellularity, with 
most cells being leukemic blasts.
A diagnosis of precursor B ALL was made on the basis of 
the 2008 WHO classification system. Chemotherapy with 
vincristine and prednisolone was performed. Fourteen days 
after relapse, the patient’s BM still showed 20% cellularity 
with persistence of blasts among nucleated cells. Unfortu-
nately, chemotherapy was discontinued because of pneu-
monia and sepsis, and he died of progressive pneumonia.
DISCUSSION
Although conversions from ALL to AML have been re-
ported, lineage switches from AML to ALL are rare (Table 2) 
[1, 6-14]. Further, to our knowledge, this is the first study to 
report a case of conversion from erythroleukemia to ALL.
Several hypotheses have been proposed to explain lineage 
switches in acute leukemia [13, 15-17]. According to the 
common myeloid/lymphoid progenitor cell hypothesis, un-
A B
Fig. 1. Findings of the bone marrow aspirate analysis (Wright stain,×1,000). (A) Erythroleukemia (AML-M6a) at initial diagnosis showed medium-sized myelo-
blasts with a moderate amount of cytoplasm without vacuoles, although a few blasts contained cytoplasmic vacuoles. (B) Precursor B cell ALL at relapse showed 
lymphoblasts that contained cytoplasmic vacuoles.Park BG, et al.  •  Relapse from Erythroleukemia to ALL
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committed progenitor cells that have both early myeloid 
and T- or B-lymphoid markers lose 1 lineage marker during 
the maturation process and differentiate toward the other 
lineage [15]. This hypothesis has been supported by the 
spontaneous lineage switches in the blast transformation 
phase of chronic myeloid leukemia [16]. According to the 
primary chemotherapy-related hypotheses, the predomi-
nant leukemic clone may be suppressed by chemotherapy, 
allowing the expansion of subclones with different pheno-
types [13, 17].
According to the secondary chemotherapy-related hy-
potheses, AML may arise because of the cytotoxic effects of 
conditioning regimens and chromosomal abnormalities, 
particularly of chromosomes 5 and 7, and 11q23 transloca-
tions that occur preferentially during the malignant trans-
formation of pluripotent stem cells [18]. In some cases, 
topoisomerase II inhibitors (epipodophyllotoxins and an-
thracyclines) affect secondary AML; for example, second-
ary AML occurring after anthracycline treatment of a pa-
tient with acute promyelocytic leukemia has been reported 
to be associated with cytogenetic abnormalities involving 
chromosomes 5 and 7 [18]. Secondary ALL, however, is 
very rare and is associated with only a few fusion genes, 
such as IgA and T-cell receptor gene rearrangements [18].
Our patient was treated with cytarabine and daunorubi-
cin (anthracycline) and had chromosomal abnormalities 
involving chromosomes 5 and 7 during both the initial di-
agnosis and the relapse. A few additional cytogenetic ab-
normalities, such as monosomy 3 and 4, appeared after the 
lineage switch, indicating that a treatment-related lineage 
switch had occurred. However, the leukemic blasts at initial 
diagnosis already showed 2 kinds of morphology, and the 
small proportion of blasts observed at the initial diagnosis 
grew, becoming predominant at relapse. Moreover, the pa-
tient’s leukemia relapsed with lineage conversion only 4 
months after the initial diagnosis, with the same leukemic 
clones showing complex karyotypic abnormalities. These 
findings suggest that a previously existing small population 
of lymphoid progenitor cells expanded during relapse. 
However, the small portion of blasts observed at the pri-
mary diagnosis was negative for PAS stain, and the immun-
ophenotype of the blasts was not representative of a mixed 
populations of blasts. Thus, these findings were more sup-
portive of the dedifferentiation of common myeloid/lym-
phoid progenitor cells.
In most patients with a lineage switch, leukemic blasts 
observed at relapse differ in morphology from the primary 
blasts; this may include differences in cell size, amount of 
cytoplasm, or presence of Auer rods. In rare cases of lineage 
switch, however, the primary and relapsed blasts have a sim-
ilar morphology [19]. Most patients who had leukemia with 
lineage switch showed relapse after 1-4 yr from the initial 
diagnosis of leukemia [1]. In some cases, very early relapse 
with lineage switch had been reported only 3 months after 
Table 1. Laboratory findings of the patient at diagnosis and at relapse
Diagnosis Relapse with conversion
Blast morphology Small to medium size with  
dispersed nuclear chromatin, 
2 or 3 prominent nucleoli, and a 
moderate amount of cytoplasm 
Large, irregular size, fine chro-
matic pattern, inconspicuous 
nucleoli, light blue cytoplasm, 
and many cytoplasmic vacuoles
Cytochemistry
  MPO
  PAS
  ANBE
Positive
Negative
Negative
Negative
Positive 
(coarse granular pattern)
Negative
Immunophenotype of blasts*
CD45
CD34
TDT
CD13
CD33
CD117
CD65
CD15
CD14
CD41
CD10
CD19
CD2
CD3
CD7
cCD22
cCD3
CD56
Glycophorin-A
CD19/CD13 
  coexpression
IHC CD79α
Anti-MPO
Intermediate
†
Positive
Negative
Positive
Positive
Positive
Positive
Positive
Negative
Negative
Negative
Positive
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Positive
Negative
Not tested
Intermediate
Positive
Positive
Positive
Negative
Negative
Positive
Positive
Negative
Negative
Negative
Positive
Negative
Negative
Negative
Positive
Negative
Negative
Negative
Positive
Positive
Negative
Cytogenetic 
  analysis
41,XY,-5,-7,add(11)(q23),der 
(14;21)(q10;q10),-16,add(17)
(p13),-18,-20,-21,-22,+2mar[20]
41,XY,add(1)(q21),-3,add(3)
(q22),-4,-5,-7,der(9)t(9;11)
(q34;q13),der(11)del(11)
(p11.2)add(11)(q23),der(14;21) 
(q10;q10),-16,add(17)(p13), 
-18,-20,-22,+4mar[20]
FLT3-ITD and FLT3-
  TKD mutations
Negative Negative
*‘Positive’ was defined as stained blasts that showed higher fluorescence than iso-
type control. 
†Intermediate: fluorescence intensity of CD45 for blasts.
Abbreviations: MPO, myeloperoxidase; PAS, periodic acid Schiff; ANBE, α-naphthyl 
butyrate esterase; TDT, terminal deoxynucleotidyl transferase; IHC, immunohistoche-
mistry; FLT3-ITD, fms-like tyrosine kinase 3-internal tandem duplications; TKD, tyro-
sine kinase domain.84     www.kjlm.org
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Table 2. Reported cases of lineage switches from AML to ALL
Age (yr) Sex Time from initial 
diagnosis to relapse (months)
Diagnosis Karyotype
Reference
Primary* Relapse
† Primary Relapse
Child 8 M 13 M5 L1 ND Normal [6]
5 M 12 M4 L1 Normal Normal [1]
2 F 12 M2 L1 del(11) Normal [7]
0 F 13 M5 L1 46,XX,t(9;11)(p22;q21) Complex karyotype without t(9;11) [8]
2 F 11 M1 L1 46,XX,t(9;11)(p22;q23) Normal [9]
0 F 1 M5 L2 46,XX,t(4;11)(q21;q23) 46,XX,t(4;11)(q21;q23) [10]
4 M 9 M5 Pro-B Normal Normal [11]
Adult 39 F 12 M1 CALL ND ND [12]
46 M 10 M4 L2 Normal Normal [13]
38 M 58 M4e Pre-B 46,XY,inv(16)(p13q22) ND but inv(16)(p13q22) positive by FISH [14]
62 M 4 M6a Pre-B Complex karyotype including 
monosomy 5 and monosomy 7
Complex karyotype including monosomy 5 
and monosomy 7, with some clonal switch
Present case
*Primary leukemia was diagnosed according to the FAB classification. 
†Relapsing leukemia was diagnosed according to the FAB or WHO classification.
Abbreviations: M, male; F, female; ND, not done; Pro-B, pro-B lymphoblastic leukemia; CALL, common cell ALL; Pre-B, precursor B-cell lymphoblastic leukemia.
the initial diagnosis [3].
It is not always possible to perform the full panel of im-
munophenotyping assays in cases of relapsing leukemia; 
therefore, the frequency of the lineage switch phenomena 
could be underestimated. The treatment of AML is com-
pletely different from that of ALL. Thus, it is important that 
sufficient immunophenotypic markers for relapsing leuke-
mia be employed to arrive at the correct diagnosis. Correct 
diagnosis and early recognition of lineage switch is impor-
tant for effective therapeutic intervention.
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